| Onoact (landiolol) / Ono Pharma |
2017-002138-22: Study the effect of Landiolol on elevated heart rate by septic shock patients |
|
|
| Ongoing | 4 | 200 | Europe | RAPIBLOC (Landiolol hydrochloride lyophilized powder 300 mg/50 ml), Powder for infusion, Rapibloc 300 mg Pulver zur Herstellung einer Infusionslösung | AOP Orphan Pharmaceuticals AG, AOP ORPHAN PHARMACEUTICALS AG, AOP Orphan Pharmaceuticals AG, AOP Pharmaceuticals AG | Adult patients in ICU with septic shock who remain tachycardic (HR ≥95 bpm) and require vasopressor therapy to maintain a Mean arterial pressure (MAP) of ≥65 mmHg after a hemodynamic optimization period (at least 12 hours and up to 36 hours)., Septic shock / Tachycardia, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 4 | 1500 | Europe | Landiolol, Placebo | Università Vita-Salute San Raffaele | Cardiac Failure, Low Cardiac Output Syndrome | 06/27 | 12/27 | | |
2015-001129-17: Study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in children. Studie zur Untersuchung der Wirksamkeit und Sicherheit von AOP Landiolol zur Regulierung von schnellen Herzrhythmusstörungen bei Kindern. |
|
|
| Ongoing | 3 | 120 | Europe | RAPIBLOC (Landiolol hydrochloride lyophilized powder 300 mg/50 ml), LDLL300, Powder for infusion, RAPIBLOC 300 mg | AOP Orphan Pharmaceuticals AG, AOP Orphan Pharmaceuticals AG | Supraventricular tachycardia in pediatric patients. Supraventrikuläre Tachykardie bei pädiatrischen Patienten., Supraventricular tachycardia in children. Schnelle Herzrhythmusstörungen bei Kindern., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-000307-17: Microcirculatory and Macrocirculatory Effects of Landiolol on Postoperative Atrial Fibrillation Effets Microcirculatoires et Macrocirculatoires du Landiolol dans la Fibrillation Auriculaire Post-opératoire |
|
|
| Not yet recruiting | 3 | 30 | Europe | Powder for solution for infusion, RAPIBLOC 300 mg | Hospices Civils de Lyon, Laboratoire Anomed Pharma GmbH | Postoperative Atrial Fibrillation Fibrillation atriale post opératoire, Postoperative Atrial Fibrillation Fibrillation atriale post opératoire, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-002671-34: Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractlity: an open label prospective randomized study Comparaison de la prévention de la mortalité entre le Landiolol et laprise en charge standard des patients hospitalisés avec choc septique ethyperkinétique : étude ouverte prospective randomisée |
|
|
| Not yet recruiting | 3 | 360 | Europe | Landiolol, Powder for injection, RAPIBLOC 300 mg | CHU Amiens-Picardie, DGOS (PHRC N 2019), Amomed Pharma SAS | septic shock with hypercontractlity choc septique et hyperkinétique, septic shock with hypercontractlity choc septique et battement du cœur très rapide, Not possible to specify | | | | |
| Completed | 3 | 400 | Europe | Landiolol, Rapibloc, Saline, Sodium chloride 0.9% | CMC Ambroise Paré | Atrial Fibrillation, Cardiac Surgery | 06/23 | 07/23 | | |
| Recruiting | 3 | 164 | Europe | Landiolol HCl, Rapibloc, Placebo, Isotone saline solution | Medical University of Vienna | Atrial Fibrillation, Postoperative Complications | 11/23 | 06/24 | | |
| Recruiting | 3 | 44 | Europe | Landiolol, Rapibloc | Assistance Publique - Hôpitaux de Paris | Septic Shock | 01/24 | 01/24 | | |
2020-004633-21: Effets MIcrocirculatoires du LANdiolol au cours du chOc Septique |
|
|
| Not yet recruiting | 3 | 44 | Europe | Powder for solution for infusion, Landiolol (Rapibloc) | Assistance Publique -Hopitaux de Paris | effets vasculaires MIcrocirculatoires du LANdiolol au cours du chOc Septique, effets vasculaires MIcrocirculatoires du LANdiolol au cours du chOc Septique | | | | |
2017-001785-14: STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade) |
|
|
| Ongoing | 2 | 340 | Europe | Landiolol hydrochloride 300 mg lyophilised powder, Powder for solution for infusion, Landiolol hydrochloride 300 mg lyophilised powder | University Hospitals Birmingham NHS Foundation Trust | Tachycardia in Septic Shock, Rapid heart rate in patients admitted to ICU with septic shock, Body processes [G] - Immune system processes [G12] | | | | |
2020-003661-19: Landiolol for improved outcome in cardiac arrest Der Einsatz von Landiolol für ein besseres Outcome in Patienten mit Herzkreislaufstillstand |
|
|
| Not yet recruiting | 2 | 32 | Europe | Rapibloc, Powder for concentrate for solution for injection/infusion, Rapibloc® | Medical University of Vienna, AMOMED | out-of-hospital cardiac arrest präklinischer Herzkreislaufstillstand, out-of-hospital cardiac arrest präklinischer Herzkreislaufstillstand, Not possible to specify | | | | |
| Recruiting | 1/2 | 32 | Europe | Landiolol, Onoact, Rapibloc, Sodium Chloride (NaCl) 0.9%, NaCl | Medical University of Vienna | Cardiac Arrest | 12/23 | 12/23 | | |
ChiCTR-TRC-12003021: Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multi-center, randomized, double-blind, placebo-controlled study |
|
|
| Completed | 1 | 240 | | Placebo ;Landiolol | Renji Hospital, Medical School of Shanghai Jiaotong University; Renji Hospital, Medical School of Shanghai Jiaotong Universi, Chongqing LUMMY Pharmaceutical Co.,Ltd | intraoperative supraventricular tachycardia | | | | |
| Active, not recruiting | N/A | 400 | Japan | Onoact (landiolol) - Ono Pharma | Fujita Health University, Ono Pharmaceutical Co., Ltd. | Non-small cell lung cancer | | | | |
LARISA, NCT04694092: Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation |
|
|
| Recruiting | N/A | 40 | RoW | Intensive heart rate control with landiolol, Rapibloc, Amomed Pharma, Austria, Standard approach to heart rate control | Institute for Clinical and Experimental Medicine | Atrial Fibrillation, Atrial Fibrillation Rapid, Acute Heart Failure, Left Ventricular Dysfunction | 12/23 | 12/23 | | |
HyperBetashock, NCT04748796: Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility |
|
|
| Recruiting | N/A | 360 | Europe | echocardiography, Landiolol | Centre Hospitalier Universitaire, Amiens, CH Dieppe, CH Elbeuf, CH Le Havre, Centre Hospitalier de Beauvais, CH Compiègne, CH Laon, University Hospital, Caen, CH Cherbourg, University Hospital, Lille, CH Douai, CH Montreuil, Centre Hospitalier de Roubaix, Centre Hospitalier de Bethune, CH Lomme, Centre Hospitalier de Lens, Tourcoing Hospital, Centre Hospitalier VALENCIENNES, Centre Hospitalier Arras, Hospital Ambroise Paré Paris, University Hospital, Brest, Henri Mondor University Hospital, Hospital Avicenne, University Hospital, Montpellier, CH Calais, Hôpital Edouard Herriot, Centre Hospitalier Universitaire de Nīmes, Groupe Hospitalier Pitié-Salpêtrière | Septic Shock, Tachycardia, Mortality During Septic Shock, Beta-blocker | 02/24 | 03/24 | | |
